Guerbet Announces Solid Growth and Improved Profitability in 2023 Full-Year Results

Guerbet (FR0000032526 GBT) has published its 2023 financial year consolidated statements, demonstrating a steady performance with €785.7m in revenue. This reflects a 5.9% increase on a like-for-like basis and at constant exchange rates (CER), aligning with its target of more than 5% growth. The company observed strong growth momentum in Asia and the EMEA region, while the Americas saw a slight decline mitigated by a Q4 catch-up.

The reported restated EBITDA margin was 13.1%, surpassing the forecasted target. Guerbet also projected optimistic revenue growth of over 8% and an improvement in its restated EBITDA margin for 2024. This positive outlook is supported by the company's strategic developments, including the commercial launch of Elucirem™ in the US and key European markets and enhanced operations in Asia, notably China.

EBITDA held strong at 12.6% and net income saw a significant recovery to €22.2m, contrasting sharply with the previous year's loss. This improvement was attributed to better cost management and a more profitable product mix. Additionally, Guerbet announced a stable dividend of €0.50 per share for 2023 and anticipates continued strategic growth and profitability enhancements in the coming year.